Article
IgG1 heavy chain-coding gene polymorphism (G1m allotypes) and development of antibodies-to-infliximab.
Pharmacogenetics and genomics - 1 May 2009
Magdelaine-Beuzelin Charlotte, Vermeire Séverine, Goodall Margaret, Baert Filip, Noman Maja, Assche Gert Van, Ohresser Marc, Degenne Danielle, Dugoujon Jean-Michel, Jefferis Roy, Rutgeerts Paul, Lefranc Maire-Paule, Watier Hervé
Abstract excerpt
OBJECTIVE: The chimeric anti-tumor necrosis factor-alpha antibody infliximab is known to induce antibodies-to-infliximab (ATI) in some treated patients. Immunogenicity in murine variable domains is expected; however, constant domains of its human heavy gamma1 chain may also be implicated as it expresses G1m1 and G1m17 allotypes. This allelic form may be immunogenic in patients that are homozygous for the G1m3...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
